Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Matthew I MilowskyPeter H O'DonnellChristopher J HoimesDaniel P PetrylakThomas W FlaigHelen H MoonTerence W FriedlanderNataliya MarRana R McKaySandy SrinivasGwenaëlle GravisChethan RamamurthyManojkumar BupathiSergio BracardaPhoebe WrightZsolt HeppAnne-Sophie CarretYao YuRyan DillonRitesh KatariaJennifer L BeaumontIntan PurnajoJonathan E RosenbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
EV + P in patients with la/mUC who were cisplatin-ineligible was associated with preservation or improvement of QOL/functioning/symptoms. Improvement in pain was seen in both PRO instruments and treatment arms. These data complement clinical outcomes of 1L EV + P.
Keyphrases
- patient reported outcomes
- chronic pain
- papillary thyroid
- pain management
- high grade
- neuropathic pain
- squamous cell
- hodgkin lymphoma
- sleep quality
- squamous cell carcinoma
- anti inflammatory
- spinal cord
- spinal cord injury
- machine learning
- urinary tract
- combination therapy
- replacement therapy
- smoking cessation
- postoperative pain